Igalmi
Igalmi (dexmedetomidine) is a selective alpha-2 adrenergic receptor agonist. It is formulated as a sublingual film and is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adult patients.
Dosage by Body Weight
Must be administered under the supervision of a healthcare provider. The standard dose is 120 mcg to 180 mcg based on agitation severity. For geriatric patients (65 and older) or patients with hepatic impairment, a starting dose of 90 mcg is recommended. Place the film sublingually or buccally and allow it to dissolve completely. Do not chew or swallow the film.
- Body Weight
- Below 5 kg
- Dose
- Not indicated
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy of Igalmi have not been established in pediatric patients. Not recommended for patients under 18 years of age.
- Body Weight
- 5-7 kg
- Dose
- Not indicated
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy of Igalmi have not been established in pediatric patients. Not recommended for patients under 18 years of age.
- Body Weight
- 8-10 kg
- Dose
- Not indicated
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy of Igalmi have not been established in pediatric patients. Not recommended for patients under 18 years of age.
- Body Weight
- 11-15 kg
- Dose
- Not indicated
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy of Igalmi have not been established in pediatric patients. Not recommended for patients under 18 years of age.
- Body Weight
- 16-20 kg
- Dose
- Not indicated
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy of Igalmi have not been established in pediatric patients. Not recommended for patients under 18 years of age.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not indicated | Not applicable | Safety and efficacy of Igalmi have not been established in pediatric patients. Not recommended for patients under 18 years of age. |
| 5-7 kg | Not indicated | Not applicable | Safety and efficacy of Igalmi have not been established in pediatric patients. Not recommended for patients under 18 years of age. |
| 8-10 kg | Not indicated | Not applicable | Safety and efficacy of Igalmi have not been established in pediatric patients. Not recommended for patients under 18 years of age. |
| 11-15 kg | Not indicated | Not applicable | Safety and efficacy of Igalmi have not been established in pediatric patients. Not recommended for patients under 18 years of age. |
| 16-20 kg | Not indicated | Not applicable | Safety and efficacy of Igalmi have not been established in pediatric patients. Not recommended for patients under 18 years of age. |
Formulation
Purpose
Acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults
Generic Name
Dexmedetomidine hydrochlorideScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.